神偷奶爸3

Here’s Why Ranbir Kapoor Wants Love & War to Release in June 2026 ?_我的网站

一 |     Ranbir Kapoor currently has two big projects in development: Nitesh Tiwari's Ramayana and Sanjay Leela Bhansali's Love & War.  Ramayana is planned as a two-part film, with releases scheduled for Diwali in 2026 and 2027. The release date for Love & War has not yet been announced. However, according to a report from Bollywood Hungama, Ranbir is reportedly wanting Bhansali's film to be released by June 2026.           Reportedly, Ranbir wants to maintain a minimum four-month gap between the releases of Love & War and Ramayana. Given that Ramayana is ideally suited for a Diwali release, he has reportedly requested Sanjay Leela Bhansali to release Love & War in theatres latest by June 2026.           However, a source close to the film also informed that Bhansali is interested in releasing Love & War in August, coinciding with Independence Day. The source said, “But RK feels that there’s too little of a gap between Love & War and Ramayana. He is firm on his stance of releasing Love & War in June. Ranbir’s producer, Namit Malhotra too, is putting the pressure to ensure that SLB releases Love & War in June, as he doesn’t want the aftermath of Love & War to impact Ramayana in any way, given that the latter is a much bigger film.”            The source added, “The makers of Love & War starring Ranbir Kapoor, Vicky Kaushal & Alia Bhatt are eyeing a June 5, 2026 release. Slated exactly a week after the IPL finale and coinciding with summer holidays, the date offers a prime launchpad for a big-ticket spectacle like Love & War. With no immediate box-office clutter and a high footfall period, this could be a strategic move to maximise the film’s reach.”            Earlier this year, during a meet and greet event in Mumbai, Ranbir Kapoor discussed the project, saying, “Love & War is something which is every actor’s dream. To work with brilliant actors like Alia and Vicky and to be directed by the master, Sanjay Leela Bhansali. I worked with him 17 years ago. To work with him again, I can say this with so much of clarity that I haven’t met a human being who works so hard, who understands characters, emotions, music, Indian culture, Indian value system, as much as Sanjay Leela Bhansali. Just to be on his set, it is tiring. It is long. The process can be a little daunting but eventually, as an artist, it is so satisfying. He really nurtures art. As actors, it’s truly been amazing so far.”      Also Read: Photos: Ranbir Kapoor and Alia Bhatt’s On-set Stills From SLB’s Love and War Break The Internet。    Shares of Pfizer are in retreat on the first day of trading after the drug company said sales of its COVID-19 vaccine and its coronavirus treatment are weaker than it had expected and cut revenue projections by $9 billion for the year. Falling sales of both clipped sales in the second quarter, but Pfizer said in August that it expected a rebound in the second half of 2023. Shares of Pfizer slipped more than 1% before the opening bell Monday and Moderna, which is heavily reliant on the competing vaccine it makes, slid nearly 5%. Pfizer said Friday that global usage of Paxlovid is trending slightly above last year, but that it's still below expectations.The fall vaccination period just began and the New York City drugmaker said that it's too soon to get a handle on vaccination rates for the year.Full-year revenue for Paxlovid and Comirnaty is expected to be approximately $12.5 billion, short $9 billion of what it had expected. Pfizer is lowering its full-year revenue expectations for Paxlovid by approximately $7 billion. That number also accounts for delayed commercialization of the product, which was pushed to January 2024 from the company's previous expectation of commercialization in the second half of this year. Pfizer is also lowering its 2023 revenue expectations for Comirnaty by approximately $2 billion due to lower-than-expected vaccination rates.Pfizer Inc. now foresees 2023 revenue in a range of $58 billion to $61 billion, down from its prior forecast for $67 billion to $70 billion. It now projects full-year adjusted earnings between $1.45 and $1.65 per share due to lower-than-anticipated revenue for COVID-19-related products and inventory write-offs.That is short of the full-year revenue of $63.61 billion and earnings of $2.77 per share that Wall Street was expecting, and far short of the company's previous projections of per-share earning between $3.25 and $3.45. JPMorgan said the company's update solves an ongoing U.S. Paxlovid inventory debate and it anticipates the company's bigger-than-expected cuts to its sales projections will help put a floor under per-share earnings expectations for next year.。

Current article:http://rucrhxo.dingruorenhongqiaminmeipeiliu.cyou/news/20260826_5901116.html

Published on:09:47:40